REFERENCES

Questions? Call 1-800-423-2090
Intended for a US Healthcare Professional Audience Only.

References

  1. Obizur [Prescribing Information]. Westlake Village, CA: Baxter Healthcare Corporation; October 2014.
  2. FDA approves new treatment for rare form of hemophilia [press release]. Silver Spring, MD: U.S. Food and Drug Administration; October 24, 2014.
  3. Data on file. Baxter Healthcare Corporation.
  4. Quantitative assays: the Bethesda assay. Practical-Haemostasis.com. http://practical-haemostasis.com/Factor%20Assays/inhibitor_assays.html. Accessed May 26, 2015.
  5. Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015;21(2):162-170.
  6. Collins P, Baudo F, Huth-Kühne A, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010;3:161.
  7. U.S. and World Population Clock. United States Government Census Web site. http://www.census.gov/popclock. Accessed June 3, 2014.
  8. Franchini M, Mannucci PM. Acquired hemophilia A: a 2013 update. Thromb Haemost. 2013;110(6):1114-1120.
  9. Grethlein SJ, Besa EC, Kessler CM, et al. Acquired hemophilia. Medscape. http://emedicine.medscape.com/article/211186-overview#showall. Accessed May 18, 2015.
  10. Knoebl P, Marco P, Baudo F, et al, on behalf of the EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-631.
  11. Hemophilia: Facts. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/ncbddd/hemophilia/facts.html. Accessed June 3, 2015.
  12. US National Institutes of Health Web site. www.clinicaltrials.gov. Accessed September 22, 2014.